After 27 years with J&J — starting in consumer products and rising to the position of EVP and head of the company’s medical devices group — McEvoy gave her notice on Friday “to pursue new opportunities,” she said today.
McEvoy will stay on into the company’s first quarter, which starts in January 2024.
Medical Design & Outsourcing: Ashley McEvoy joins J&J’s top-paid executives
New Brunswick, New Jersey-based J&J has already appointed Tim Schmid, most recently J&J MedTech Asia Pacific (APAC) company group chair, as a J&J EVP and J&J MedTech’s new worldwide chair.
“It is no overstatement to say that my time at J&J — and in particular leading the MedTech business, our team of more than 70,000 colleagues worldwide — has been the honor and privilege of my career,” McEvoy wrote on LinkedIn. “Thanks to our team, we have brought to life entirely new standards of care and driven innovation to save lives, with products that are used in more than 75 million procedures each year and new technologies that have resulted in achievements never before possible.”
J&J MedTech rebranded last year from J&J Medical Devices in an effort to reflect J&J”s “global leadership as a medtech innovator positively impacting the health of millions of patients around the world,” McEvoy said at the time.
Earlier this year, J&J was among medtech developers that cut jobs. J&J spun off its consumer health business as Kenvue in August and last month dropped its iconic logo while rebranding its pharma business. Most recently, the company announced a restructuring of its DePuy Synthes orthopedic business last week.
Beyond DePuy Synthes (which includes J&J’s Velys surgical robotics program), J&J MedTech’s portfolio includes Ethicon, Mentor, Acclarant, Biosense Webster, Cerenovus and J&J Vision.
“I’m proud of the way we have transformed the MedTech business into a growth-focused innovator: together over the past five years we have taken our growth from 1.5% to 8%, deployed more than $22 billion in capital in acquisitions, and pushed into new markets including heart failure, vision, and a robotics business we built from scratch,” McEvoy continued.
McEvoy said she is “beyond confident” that Schmid is the right leader to take the business forward.
“Tim is more than just my successor,” she continued. “He is a trusted friend and partner. When I had my fourth child, Tim ran the business while I was on leave, and when I went to run Vision, he backfilled my role as Worldwide President of Ethicon, so it’s both fitting and meaningful that I am passing the baton to him now. ”
J&J CEO and Chair Joaquin Duato — who stepped up into the corner office in 2022 — credited McEvoy for leading the company’s medtech transformation, “resulting in improved performance and allowing us to better meet the needs of patients and consumers around the world.”
“Her leadership of people and commitment to their development has been a hallmark of her tenure,” Duato said in a news release. “I wish her all the best in the next chapter of her career.”
McEvoy is also the chair of the Advanced Medical Technology Association (AdvaMed), serving a two-year term that started earlier this year. She’ll step down from that leadership role, the medtech industry group told MassDevice.
More: Who is Tim Schmid, Johnson & Johnson MedTech’s new leader?
